New drug combo shows promise for tough leukemia cases

NCT ID NCT02997761

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of two drugs, ibrutinib and blinatumomab, in 19 adults with B-cell acute lymphoblastic leukemia that had come back or wasn't responding to treatment. The goal was to see how many patients achieved complete remission. The study is completed, and results will help determine if this approach is worth further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ibrutinib and blinatumomab
What this could lead to
If it works, this combination could offer a new treatment option for patients whose leukemia has returned or stopped responding to standard therapy.
What could go wrong
This is a small, early-phase trial with only 19 participants, so results may not apply to everyone. Side effects from the drugs can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT B ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.